Infertility is a global health issue as its affects both men and women. Infertility in females occur due to increasing age, polycystic ovarian syndrome (PCOS), obesity, and multiple miscarriages whereas in males infertility occur due to erectile dysfunction, low sperm count, abnormal sperms, etc. Increasing prevalence of infertility is expected to propel demand for the infertility drugs. According to World Health Organization (WHO) 2012 report, infertility affects one out of four couples in emerging economies. Many researchers are working towards finding an efficient treatment for the infertility. For instance, in 2018 at Ben-Gurion University (BGU), Israel researchers were developing a new, single-dose infertility treatment based on a new compound. The new treatment, developed by the BGU researchers, stimulates the expression of the telomerase and re-elongates the telomeres, protecting the cells from damage.
The global infertility drugs market size was valued at US$ 3.8 billion in 2017, and is expected to witness a CAGR of 5.8% over the forecast period (2019 – 2026).
Global Infertility Drugs Market Share (%) Analysis, By Product Type, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing Research & Development for More Effective Treatment with Lesser Side-Effects to Reduce Infertility is expected to Drive Growth of the Infertility Drugs Market
The infertility drugs market size is expected to witness significant growth, owing to the rising research and developmental studies for more effective treatment to achieve pregnancy and live births. For instance, in 2014, a team of researchers at National Institutes of Health’s (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) found that women treated with Letrozole have high rates of ovulation and live births than women treated with the standard drug, Clomiphene. Furthermore, among women who received Letrozole, 27.5% of them eventually had a live birth and women who received clomiphene, only 19.1% them experienced a live birth. The cumulative ovulation rate was higher for the Letrozole group, with ovulation occurring 61.7% of the time, and the women in the clomiphene group ovulated 48.3% of the time.
Moreover, rising prevalence of lifestyle disorders and unhealthy diet such as obesity, stress, smoking, diabetes, Poly Cystic Ovarian Syndrome (PCOS) and etc. also leads to infertility, eventually rising demand for infertility drugs. According to a study published in National Center for Biotechnology and Information (NCBI) 2015 report, smoking was associated with decrease in sperm density by 15.3%, total sperm counts by 17.5%, and total motile sperm by 16.6% compared with nonsmokers in China.
Infertility Drugs Market – Restraints
The infertility drugs market growth is hindered by the side effects shown by the drugs including headache, nausea, upper respiratory tract infection, abdominal tenderness, sinus congestion, mood swings, acne, breast tenderness, weight gain, pelvic discomfort, abnormal bleeding or spotting, vomiting, injection site pain, redness, dizziness and Ovarian Hyper-Stimulation Syndrome (OHSS). According to a study published in NCBI, in 2016, up to 10% to 20% of women who consume infertility drugs can develop a mild form of OHSS, which will usually resolve on its own. Severe cases of OHSS occurs in less than one percent of patients in the U.S.
Infertility Drugs Market - Regional Insights
On the basis of region, the global infertility drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global infertility drugs market size, owing to the rising number of new Food and Drug Administration (FDA) infertility drug approvals over the forecast period. For instance, in 2018, Zydus Cadila launched generic Vardenafil Hydrochloride tablets used for the treatment of erectile dysfunction in the U.S. The company has launched the tablets in the strengths of 2.5 mg, 5 mg, 10 mg and 20 mg.
Asia Pacific infertility drugs market size is expected to foresee a rapid growth in the market, owing to rise in research and development activities for better reproductive health. For instance, in 2018, Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) announced a long-term collaboration to advance basic and translational research in reproductive medicine through the development of novel product candidates and therapeutic strategies.
Global Infertility Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2026
Source: Coherent Market Insights Analysis (2019)
Infertility Drugs Market - Competitive Landscape
Key players operating in the global infertility drugs market include Merck & Co., Ferring Pharmaceuticals, LIVZON Pharmaceutical Group Inc., Abbott Laboratories, Bayer AG, and Zydus Pharmaceuticals.
In order to treat infertility problems among the population there are many dugs present in the market such as Clomiphene (Clomid), Letrozole (Femara), Gonadotropins, etc. These drugs are used to trigger ovulation or to trigger hormones for proper functioning of ovaries. According to data published in 2018, in Shady Grove Fertility, Clomiphene is being prescribed by doctors for more than 50 years and still being extensively used to treat infertility cases in women. High blood sugar levels and Poly Cystic Ovarian Syndrome (PCOS) also interferes in sustaining pregnancy. To control the blood sugar and PCOS Metformin is highly prescribed drug. Metformin is sold under the brand name of Glucophage, Glumetza, Glucophage XR, and Fortamet.
Increasing prevalence of infertility in couples is highly contributing to infertility drugs market size. For instance, According to Centres for Disease Control and Prevention (CDC) report of 2018, about 6% of women aged 15 to 44 years in the U.S. were unable to get pregnant after one year of trying (infertility). Also, about 12% of women aged 15 to 44 years in the U.S. have difficulty getting pregnant or carrying a pregnancy to term. Infertility also affects rising number of men. According to the same source, almost 9% of men aged 25 to 44 years in the U.S. reported that they required medical help for reproduction.
The restraining factors for the infertility drug market growth is the potential risks of infertility drugs. Risks of infertility includes pregnancy with multiples, ovarian hyper-stimulation syndrome, long-term risks of ovarian tumours etc. According to the data published by Mayo Clinic Organisation in 2018, oral medications have less risk of multiples pregnancy (less than 10 percent) and mostly a risk of twins. And according to the same source, chances increase up to 30 percent with injectable medications. Injectable fertility medications also carry the major risk of triplets or more (higher order multiple pregnancy).
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.